HIV/AIDS Elite Suppressors: HIV suppression maintained in HLA-B*57+ elite suppressors despite CTL escape mutations

AIDSWEEKLY Plus; Monday, August 14, 2006
Staff Medical Writers

According to a study from the United States, "Rare human immunodeficiency virus 1-infected individuals, termed elite suppressors (ES), maintain plasma virus levels of <50 copies/mL and normal CD4 counts without therapy.

"The major histocompatibility complex class I allele group human histocompatibility leukocyte antigen (HLA)-B*57 is over-represented in this population. Mutations in HLA-B*57 restricted epitopes have been observed in ES, but their significance has remained unclear."

"Here we investigate the extent and impact of cytotoxic T lymphocyte (CTL) escape mutations in HLA-B*57+ ES. We provide the first direct evidence that most ES experience chronic low level viremia," J.R. Bailey and colleagues at Johns Hopkins University reported.

"Sequencing revealed a striking discordance between the genotypes of plasma virus and archived provirus in resting CD4+ T cells. Mutations in HLAB* 57-restricted Gag epitopes were present in all viruses from plasma but were rare in proviruses, suggesting powerful selective pressure acting at these epitopes.

"Surprisingly," said the authors, "strong CD8+ T cell interferon-gamma responses were detected against some mutant epitopes found in plasma virus, suggesting the development of de novo responses to viral variants. In some individuals, relative CD8+ T cell interleukin-2 responses showed better correlation with the selection observed in vivo."

Scientists concluded, "Thus, analysis of low level viremia reveals an unexpectedly high level of CTL escape mutations reflecting selective pressure acting at HLA-B*57 restricted epitopes in ES. Continued viral suppression probably reflects CTL responses against unmutated epitopes and residual or de novo responses against epitopes with escape mutations."

Bailey and colleagues published the results of their research in the Journal of Experimental Medicine (Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. J Exp Med. 2006 May 15;203(5):1357-69).

For additional information, contact J.N. Blankson, Johns Hopkins University, School Medical, Dept. of Medical, Baltimore, MD 21287, USA.

The publisher of the Journal of Experimental Medicine can be contacted at: Rockefeller University Press, 1114 First Avenue, 4TH FL, New York, NY 10021, USA.

Keywords: Baltimore, Maryland, United States, HIV/AIDS, Elite Suppressor, Viremia, CTL Escape Mutant, Human Histocompatibility Leukocyte Antigen.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Bailey JR, Williams TM, Siliciano RF, et al., “Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations”, J Exp Med. 2006 May 15;203(5):1357-69.

PubMED Related articles Search

2006-08-14
AW060806

Copyright © 2006 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.